- Home
- FUSB vs GOSS Comparison
FUSB vs GOSS Comparison
Compare FUSB & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FUSB | GOSS |
|---|---|---|
| Founded | 1952 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.4M | 83.2M |
| IPO Year | 1995 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FUSB | GOSS |
|---|---|---|
| Price | $16.50 | $10.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $4.19 |
| AVG Volume (30 Days) | 35.7K | ★ 13.2M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | N/A | ★ $48,471,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $201.64 |
| P/E Ratio | $25.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.00 | $0.11 |
| 52 Week High | $16.99 | $12.52 |
Technical Indicators
Market Signals| Indicator | FUSB | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 48.94 | 95.73 |
| Support Level | $15.75 | $0.19 |
| Resistance Level | $16.50 | N/A |
| Average True Range (ATR) | 0.20 | 0.29 |
| MACD | 0.02 | 1.22 |
| Stochastic Oscillator | 21.09 | 82.71 |
Price Performance
Historical ComparisonAbout FUSB First US Bancshares Inc.
First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement accounts, and time deposits, personal and commercial loans, safe deposit box services, and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals, and other individuals.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).